7.71
price up icon3.49%   0.26
after-market アフターアワーズ: 7.92 0.21 +2.72%
loading
前日終値:
$7.45
開ける:
$8
24時間の取引高:
33.73M
Relative Volume:
11.59
時価総額:
$698.24M
収益:
$30.91M
当期純損益:
$-209.47M
株価収益率:
-2.3168
EPS:
-3.3279
ネットキャッシュフロー:
$-147.13M
1週間 パフォーマンス:
-6.72%
1か月 パフォーマンス:
+2.66%
6か月 パフォーマンス:
+25.57%
1年 パフォーマンス:
-14.33%
1日の値動き範囲:
Value
$6.70
$8.955
1週間の範囲:
Value
$6.70
$8.955
52週間の値動き範囲:
Value
$3.43
$10.82

Verastem Inc Stock (VSTM) Company Profile

Name
名前
Verastem Inc
Name
セクター
Healthcare (1051)
Name
電話
(781) 292-4200
Name
住所
117 KENDRICK STREET, NEEDHAM, MA
Name
職員
102
Name
次回の収益日
2026-11-03
Name
最新のSEC提出書
Name
VSTM's Discussions on Twitter

Compare VSTM vs VRTX, MRNA, REGN, ARGX, RVMD

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
VSTM icon
VSTM
Verastem Inc
7.71 698.24M 30.91M -209.47M -147.13M -3.3279
VRTX icon
VRTX
Vertex Pharmaceuticals Inc
498.50 126.35B 12.34B 4.34B 3.71B 16.87
MRNA icon
MRNA
Moderna Inc
226.30 90.35B 2.23B -3.19B -1.60B -8.1462
REGN icon
REGN
Regeneron Pharmaceuticals Inc
778.36 80.14B 14.92B 4.42B 3.79B 41.04
ARGX icon
ARGX
Argen X Se Adr
818.30 51.46B 4.16B 1.29B 734.26M 19.58
RVMD icon
RVMD
Revolution Medicines Inc
193.52 41.48B 742.00K -1.37B -1.07B -7.0731

Verastem Inc Stock (VSTM) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2026-09-17 開始されました Wolfe Research Outperform
2026-03-12 再開されました BTIG Research Buy
2026-02-04 開始されました H.C. Wainwright Buy
2025-10-16 再開されました Cantor Fitzgerald Overweight
2025-04-10 開始されました Jefferies Buy
2025-03-24 繰り返されました H.C. Wainwright Buy
2024-12-31 繰り返されました BTIG Research Buy
2024-09-30 開始されました Guggenheim Buy
2023-11-21 再開されました BTIG Research Buy
2023-09-27 開始されました B. Riley Securities Buy
2023-06-15 アップグレード Mizuho Neutral → Buy
2022-09-07 再開されました Alliance Global Partners Buy
2022-04-29 再開されました Cantor Fitzgerald Overweight
2022-04-14 開始されました RBC Capital Mkts Outperform
2022-03-09 開始されました Truist Buy
2021-07-01 開始されました Alliance Global Partners Buy
2021-05-24 アップグレード BTIG Research Neutral → Buy
2019-06-20 ダウングレード BTIG Research Buy → Neutral
2019-05-10 ダウングレード Raymond James Outperform → Mkt Perform
2018-07-13 開始されました BTIG Research Buy
2018-05-02 開始されました Seaport Global Securities Buy
2018-03-08 開始されました B. Riley FBR, Inc. Buy
2017-09-07 繰り返されました H.C. Wainwright Buy
2017-04-13 開始されました Oppenheimer Outperform
2017-03-24 繰り返されました H.C. Wainwright Buy
2015-09-29 ダウングレード Cantor Fitzgerald Buy → Hold
2015-09-29 ダウングレード JMP Securities Mkt Outperform → Mkt Perform
2015-09-29 ダウングレード Jefferies Buy → Hold
2015-09-29 ダウングレード Raymond James Strong Buy → Outperform
2015-09-28 ダウングレード Mizuho Buy → Neutral
2015-09-28 ダウングレード ROTH Capital Buy → Neutral
2015-09-09 開始されました Raymond James Strong Buy
2015-05-12 繰り返されました UBS Buy
2015-04-08 開始されました H.C. Wainwright Buy
2015-01-23 繰り返されました ROTH Capital Buy
2014-07-08 再開されました Oppenheimer Perform
2014-02-11 開始されました Mizuho Buy
すべてを表示

Verastem Inc (VSTM) 最新ニュース

pulisher
Oct 12, 2026

Does Verastem (VSTM) Have the Potential to Rally 79% as Wall Street Analysts Expect? - Zacks Investment Research

Oct 12, 2026
pulisher
Oct 08, 2026

BTIG reiterates Buy rating on Verastem, $18 price target - TradingView

Oct 08, 2026
pulisher
Oct 06, 2026

BTIG keeps its Buy rating for Verastem stock - AD HOC NEWS

Oct 06, 2026
pulisher
Oct 06, 2026

This Insider Has Just Sold Shares In Verastem - Simply Wall Street

Oct 06, 2026
pulisher
Oct 06, 2026

This Insider Has Just Sold Shares In Verastem - Simply Wall Street

Oct 06, 2026
pulisher
Oct 06, 2026

Verastem's cancer drug sales hit $25.1M in Q2 '26; key trial data expected in October - Pluang

Oct 06, 2026
pulisher
Oct 06, 2026

Verastem: A Two-For-One Clinical Readout In October And A Commercial Launch (NASDAQ:VSTM) - Seeking Alpha

Oct 06, 2026
pulisher
Oct 06, 2026

Strength Seen in Genmab (GMAB): Can Its 10.7% Jump Turn into More Strength? - Zacks Investment Research

Oct 06, 2026
pulisher
Oct 05, 2026

Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - TradingView

Oct 05, 2026
pulisher
Oct 05, 2026

Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire

Oct 05, 2026
pulisher
Oct 05, 2026

Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance

Oct 05, 2026
pulisher
Oct 05, 2026

VSTM Reiterates by HC Wainwright & Co. -- Price Target Maintained at $18 - GuruFocus

Oct 05, 2026
pulisher
Oct 05, 2026

VSTM Reiterated by BTIG -- Price Target Maintained at $18 - GuruFocus

Oct 05, 2026
pulisher
Oct 03, 2026

Verastem Oncology Announces New RAMP 201 Molecular Profiling and External Control Arm Analyses Describing Outcomes for Avutometinib Plus Defactinib in Recurrent Low-Grade Serous Ovarian Cancer to be Presented at IGCS 2026 - BioSpace

Oct 03, 2026
pulisher
Oct 02, 2026

To cover tax withholding, Verastem (VSTM) CEO sells 44,121 shares at $8 each. - Stock Titan

Oct 02, 2026
pulisher
Oct 02, 2026

A 2,566-share sale at $8 covers vesting taxes for Verastem (VSTM) CFO Daniel Calkins. - Stock Titan

Oct 02, 2026
pulisher
Oct 01, 2026

To cover vesting taxes, Dan Paterson plans to sell 44,121 shares of Verastem (VSTM). - Stock Titan

Oct 01, 2026
pulisher
Sep 29, 2026

Preferred dividends of Verastem, Inc. – HAN:2VSA - TradingView

Sep 29, 2026
pulisher
Sep 29, 2026

Discontinued operations of Verastem, Inc. – HAN:2VSA - TradingView

Sep 29, 2026
pulisher
Sep 29, 2026

Verastem, Inc. Actuals & Estimates (HAN:2VSA) - TradingView

Sep 29, 2026
pulisher
Sep 29, 2026

Verastem (NasdaqCM:VSTM) Stock Forecast & Analyst Predictions - Simply Wall Street

Sep 29, 2026
pulisher
Sep 28, 2026

Verastem (VSTM) Shares React to Positive Two-Year Phase 2 RAMP 201 Study Results in Ovarian Cancer - GuruFocus

Sep 28, 2026
pulisher
Sep 28, 2026

Half of patients with a specific ovarian cancer mutation stayed on treatment for over a year. - Stock Titan

Sep 28, 2026
pulisher
Sep 28, 2026

Cantor Fitzgerald reiterates Overweight on Verastem stock ahead of data By Investing.com - Investing.com Nigeria

Sep 28, 2026
pulisher
Sep 28, 2026

Cantor Fitzgerald reiterates Overweight on Verastem stock ahead of data - Investing.com

Sep 28, 2026
pulisher
Sep 26, 2026

Understanding the Setup: (VSTM) and Scalable Risk - Stock Traders Daily

Sep 26, 2026
pulisher
Sep 24, 2026

Verastem to present cancer treatment study data at IGCS meeting - Investing.com

Sep 24, 2026
pulisher
Sep 24, 2026

Two ovarian cancer studies are selected for Montreal talks. One studied Japanese patients. - Stock Titan

Sep 24, 2026
pulisher
Sep 24, 2026

Verastem Oncology Announces Late-Breaking Oral Presentation of RAMP 201 Low-Grade Serous Ovarian Cancer Molecular Profiling and Tumor Biomarker Analysis at IGCS 2026 Annual Global Meeting - Business Wire

Sep 24, 2026
pulisher
Sep 23, 2026

Verastem CFO Daniel Calkins sells $423 in company stock - Investing.com

Sep 23, 2026
pulisher
Sep 23, 2026

Form 4 Verastem Inc For: 23 September - Investing.com India

Sep 23, 2026
pulisher
Sep 23, 2026

Verastem CFO Daniel Calkins sells $423 in company stock By Investing.com - Investing.com Canada

Sep 23, 2026
pulisher
Sep 23, 2026

Verastem (VSTM) CFO Daniel Calkins Sells 55 Shares, Insider Owne - GuruFocus

Sep 23, 2026
pulisher
Sep 23, 2026

After selling 55 shares, Verastem (VSTM) CFO Daniel Calkins directly owned 118,014 shares. - Stock Titan

Sep 23, 2026
pulisher
Sep 21, 2026

Verastem Highlights Ovarian Cancer Launch, KRAS G12D Program at H.C. Wainwright - Yahoo Finance

Sep 21, 2026
pulisher
Sep 21, 2026

Verastem Highlights Ovarian Cancer Launch, KRAS G12D Program at H.C. Wainwright - TradingView

Sep 21, 2026
pulisher
Sep 21, 2026

H.C. Wainwright Maintains Verastem(VSTM.US) With Buy Rating, Maintains Target Price $18 - Moomoo

Sep 21, 2026
pulisher
Sep 21, 2026

Verastem Inc. Share PriceVSTM, RNS News, Articles, Quotes, & Charts (NASDAQ:VSTM) - Proactive financial news

Sep 21, 2026
pulisher
Sep 18, 2026

Verastem's Shares Not Fully Valuing its Growth Potential, RBC Says - marketscreener.com

Sep 18, 2026
pulisher
Sep 18, 2026

Verastem's Shares Not Fully Valuing its Growth Potential, RBC Says - Yahoo Finance

Sep 18, 2026
pulisher
Sep 18, 2026

Verastem, Inc. (VSTM) Stock Analysis: Unveiling a 94% Potential Upside in the Biotech Arena - DirectorsTalk Interviews

Sep 18, 2026
pulisher
Sep 17, 2026

Verastem Repeat Insider Selling Not A Positive Indicator - Moomoo

Sep 17, 2026
pulisher
Sep 17, 2026

Wolfe Research Initiates Verastem at Outperform - Yahoo Finance

Sep 17, 2026
pulisher
Sep 11, 2026

H.C. Wainwright Maintains Verastem(VSTM.US) With Buy Rating, Maintains Target Price $18 - Moomoo

Sep 11, 2026
pulisher
Sep 11, 2026

VSTM Reiterated by HC Wainwright & Co. -- Price Target Maintained at $18 - GuruFocus

Sep 11, 2026
pulisher
Sep 11, 2026

Verastem CSO Pachter: The First RAS Drug Is a Floor, Not a Ceiling - finance.biggo.com

Sep 11, 2026
pulisher
Sep 11, 2026

VSTM Reiterated by BTIG -- Price Target Maintained at $18 - GuruFocus

Sep 11, 2026
pulisher
Sep 10, 2026

Verastem at Cantor conference: dual-track growth, big bets By Investing.com - Investing.com India

Sep 10, 2026
pulisher
Sep 10, 2026

Verastem at Cantor conference: dual-track growth, big bets By Investing.com - Investing.com Canada

Sep 10, 2026
pulisher
Sep 08, 2026

VSTM: Verastem Inc Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits

Sep 08, 2026

Verastem Inc (VSTM) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading

Verastem Inc (VSTM) インサイダートレーディング

インサイダートレーディング 関係 日付 取引 コスト #株式 値 ($) #株式総数
Dan Paterson
Officer, Director
Oct 01 '26
Proposed Sale
8.00
44,121
353,047
0
Calkins Daniel
Chief Financial Officer
Oct 01 '26
Sale
8.00
2,566
20,528
123,781
Calkins Daniel
Chief Financial Officer
Sep 21 '26
Sale
7.70
55
424
118,014
Paterson Dan
President and CEO
Aug 03 '26
Sale
5.81
1,302
7,565
589,940
Gagnon Robert E.
Director
Jul 23 '26
Proposed Sale
5.89
31,924
188,032
0
Gagnon Robert E.
Director
Jun 25 '26
Proposed Sale
4.21
21,492
90,481
0
Dan Paterson
Officer, Director
Jun 22 '26
Proposed Sale
4.18
20,871
87,241
0
Calkins Daniel
Chief Financial Officer
Jun 22 '26
Sale
4.18
4,089
17,089
117,238
Paterson Dan
President and CEO
Jun 22 '26
Sale
4.18
20,871
87,241
591,242
Gagnon Robert E.
Director
May 27 '26
Proposed Sale
4.36
20,103
87,649
0
$2.33
price down icon 3.32%
ANL ANL
$10.88
price down icon 7.44%
$3.67
price down icon 4.18%
$9.07
price down icon 2.16%
$8.51
price down icon 2.07%
$6.47
price down icon 3.58%
大文字化:     |  ボリューム (24 時間):